The effects on the coagulative and rheologic pattern of two lipid-lowering drugs, bezafibrate and simvastatin, were studied in 36 hypercholesterolemic subjects. Patients were randomly divided into two groups (18 subjects each) and received bezafibrate R 400 mg/day or simvastatin 10-40 mg/day over a twelve week period. Besides a decrease in plasma fibrinogen and fibrinopeptide A (p<0.001 both), bezafibrate induced a reduction of factor VIIc and VIIIc activity (p<0.001 both), while antithrombin 3 activity was increased (p<0.001) and the hemorheologic pattern was greatly improved (p<0.001). Simvastatin caused a slight decrease in factor VIIIc activity and a moderate reduction of beta thromboglobulin. The efficacy of bezafibrate in reducing the activation of the coagulative cascade and improving the hemorheologic pattern has been con firmed; the peculiar triglycerides- and fibrinogen-lowering effect of the drug, not observed with simvastatin, could be responsible for these modifications.
Get full access to this article
View all access options for this article.
References
1.
Wilhelmsen I. , Svarsudd K., Korsan-Bengsten K., et al: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med311:501-505, 1984.
2.
Meade TW, Brozovic M., Chakrabarti RR, et al: Haemostatic function and ischemic heart disease: Principle results of the Northwick Park Heart Study. Lancet2: 533-537, 1986.
3.
Baker IA, Eastman R., Elwood PC, et al: Haemostatic factors associated with ischemic heart disease in men aged 45 to 64 years. The Speedwell Study. Br Heart J47:490-494,1982.
4.
Van de Loo J., Prentice Crm, Beller FK, Schmid-Schonbein H: Haemorheology and thrombosis. In: The Thromboembolic Disorders, Stuttgart: FK Schattaner Verlag, 1983.
5.
Di Perri T.: Rheological factors in circulatory disorders . Angiology30:480-486, 1979.
6.
Dormandy JA: Advances in haemorheology. Practitioner226:1743-1753, 1982.
7.
Kanakaray P, Megha Singh: Influence of hypercholesterolemia on morphological and rheological characteristics of erythrocytes. Atherosclerosis76:209-218,1989.
8.
Calvert GD, Blight L., Franklin J., et al: The effect of clofibrate on plasma glucose, lipoproteins, fibrinogen and other biochemical and haematological variables in patients with mature onset diabetes mellitus. Eur J Clin Pharmacol17:355-362, 1980.
9.
Simpson IA, Lorimer AR, Walker ID, et al: Effect of ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolemia. Thromb Haemostas54:442-444,1985.
10.
Niort G., Bulgarelli A., Cassader M., et al: Effect of short term treatment with Bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis71:113-119, 1988.
11.
Reid HL, Barnes AJ, Lock PJ, et al: A simple method for measuring erythrocyte deformability. Clin Pathol9:855-861, 1976.
12.
Glanz Stanton A: Statistica per discipline Bio-Mediche. New York : McGraw-Hill, 1982.
13.
Moncloa F.: World-wide clinical experience with lovastatin-simvastatin. In: The Role of Cholesterol in Atherosclerosis: New Therapeutic Opportunities , ed. by Grundy SM, Beam AG.PhiladelphiaHanley & Belfus, Inc. p 55-64, 1987.
14.
Neri Serneri GG, Gensini GF, Abbate R., et al: Changes of coagulation and platelet functions in patients with familial type IIa hyperlipoproteinemia. In: Arteriosclerotic Brain Disease. New York: Raven Press , 1982.
15.
Elkeles RS, Chakrabarti R., Vickers M., et al: Effect of treatment of hyperlipidemia on haemostatic variables . Br Med J281:973-974, 1980.
16.
Davi G., Averna M., Novo S., et al: Effect of synvinolin on platelet aggregation and thromboxane B2 synthesis in type II hypercholerolemic patients. Atherosclerosis79:79-83, 1989.
17.
Miller GJ, Martin JC, Webster J., et al: Association between dietary fat intake and plasma factor VII coagulant activity. A predictor of cardiovascular mortality. Atherosclerosis60:269-277, 1986.
18.
Mitropuolos KA, Esnouf MP, Meade TW: Increased factor VII coagulant activity in the rabbit following diet-induced hypercholesterolemia . Atherosclerosis63:43-52, 1987.
19.
Miller GJ, Cruikshank JK, Ellis LJ, et al: Fat consumption and factor VII coagulant activity in middle-aged men. Atherosclerosis78:19-24, 1989.
20.
Bruckert E. , Carvalho De Sousa J., Giral P., et al: Interrelationship of plasma triglyceride and coagulant factor VII levels in normotriglyceridemic hypercholesterolemia. Atherosclerosis75:129-134, 1989.
21.
Mitropoulos KA, Miller GJ, Reeves Bea et al: Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis76:203-208, 1989.
